Orion Therapeutics, Inc. named a finalist for SXSW Pitch 2026 in the Healthcare, AssistiveTech & BioTech category
After receiving more than 600 applications, the SXSW Pitch Advisory Board carefully reviewed and scored each submission to identify the most promising companies. The finalists and alternates listed below represent the top emerging innovations selected through this highly competitive process.
Orion Therapeutics awarded NSF Phase II STTR grant to advance lead asset for restenosis, powered by our GENESYS™ targeted delivery platform
We are excited to announce that Orion Therapeutics has been awarded an NSF Phase II STTR grant to advance our lead asset for restenosis, powered by our GENESYS™ targeted delivery platform. This funding will support studies that both move our asset toward IND-enabling development and further validate the GENESYS™ platform as a lipopeptide-enabled lipid nanoparticle […]
Chiesi Global Rare Diseases and BioLabs announce Orion Therapeutics, Inc. as the winner of the recent US Network Golden Ticket
🎉 We’re thrilled to share some exciting news! 🎉Chiesi Global Rare Diseases and BioLabs are proud to announce Orion Therapeutics, Inc. as the winner of the recent US Network Golden Ticket!A huge congratulations to the entire team at Orion Therapeutics, Inc on this incredible achievement — well deserved!
Volunteer 40 Under 40: Recognizing alumni under the age of 40 excelling personally and professionally since completing their degree at UT
Exciting News! Our CEO, Trey Fisher, PhD has been named a 2025 Volunteer 40 Under 40 Award recipient by the University of Tennessee, Knoxville!🎉 We’re grateful for Trey’s leadership and vision as Orion Therapeutics, Inc. advances LNP-RNA delivery and genetic medicine to tackle critical health challenges. His dedication to innovation and patient impact continues to […]
Orion Therapeutics Wins Golden Ticket Challenge for Lab Space at Biolabs Tufts Launch Pad
“Orion receives Golden Ticket for a year long occupancy in BioLabs supported by Chiesi. This represents a huge opportunity for Orion to extend its footprint to Boston and advance its novel delivery platform.”
Orion Therapeutics wins LSTCON “Venture Forum”
“Orion Therapeutics Inc., a Knoxville-based therapeutic company, won this year’s “Venture Forum” and a $10,000 cash prize from Holland & Knight that brought the curtain down on LSTCON, the annual Life Science Tennessee conference held Wednesday at the Westin Hotel in Nashville.”
Orion Therapeutics Wins $100,000 in Genetic Medicine Grand Challenge
“Thrilled to Announce Orion Therapeutics as a Winner of the Eli Lilly and Company Genetic Medicine Grand Challenge! … Orion Therapeutics has been named one of the winners in the prestigious Eli Lilly and Company Genetic Medicine Grand Challenge, sponsored by Nucleate.”